Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of FcγRIIa
- 1 March 2020
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 125 (5) , 670-672
Abstract
No abstract availableKeywords
Funding Information
- Janssen Pharmaceuticals, LLC (RIVAROXDVT4004)
This publication has 7 references indexed in Scilit:
- Variation in platelet expression of FcγRIIa after myocardial infarctionJournal of Thrombosis and Thrombolysis, 2019
- External Validation of the DAPT Score in a Nationwide PopulationJACC, 2018
- FcγRIIaJACC, 2018
- Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary InterventionJAMA, 2016
- Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-upThe American Journal of Medicine, 2015
- Variability of Individual Platelet Reactivity Over Time in Patients Treated With ClopidogrelJACC, 2014
- Identification of FcγRIIa as the ITAM-bearing receptor mediating αIIbβ3 outside-in integrin signaling in human plateletsBlood, 2008